Display options
Cite
Tseng-Rogenski SS, Arredouani MS, Escara-Wilke JF, et al. A safety-modified SV40 Tag developed for human cancer immunotherapy. Drug Des Devel Ther. 2009;2:17-24
Tseng-Rogenski, S. S., Arredouani, M. S., Escara-Wilke, J. F., Neeley, Y. C., Imperiale, M. J., & Sanda, M. G. (2009). A safety-modified SV40 Tag developed for human cancer immunotherapy. Drug design, development and therapy, 217-24.
Tseng-Rogenski, Stephanie S, et al. "A safety-modified SV40 Tag developed for human cancer immunotherapy." Drug design, development and therapy vol. 2 (2009): 17-24.
Tseng-Rogenski SS, Arredouani MS, Escara-Wilke JF, Neeley YC, Imperiale MJ, Sanda MG. A safety-modified SV40 Tag developed for human cancer immunotherapy. Drug Des Devel Ther. 2009 Feb 06;2:17-24. PMID: 19920890; PMCID: PMC2761181.
Copy Download .nbib Format: NLM
Share it on

Drug Des Devel Ther. 2009 Feb 06;2:17-24.

A safety-modified SV40 Tag developed for human cancer immunotherapy.

Drug design, development and therapy

Stephanie S Tseng-Rogenski, Mohamed S Arredouani, June F Escara-Wilke, Yilin C Neeley, Michael J Imperiale, Martin G Sanda

Affiliations

  1. Department of Urology, School of Medicine, University of Michigan, Ann Arbor, MI, USA.

PMID: 19920890 PMCID: PMC2761181

Abstract

Simian virus 40 (SV40)-like DNA sequences have been found in a variety of human tumors, raising the possibility that strategies targeting SV40 may provide a potential avenue for immunotherapy directed against SV40 large T Antigen (Tag)-expressing tumors. We generated a recombinant vaccinia (vac-mTag) expressing mTag and herein assessed the ability of mTag to transform cells and to interact with anti-oncoproteins, as well as screened for the presence of potential HLA-A2.1-restricted epitopes within mTag. We found that transfection of cells with mTag did not lead to their transformation. Also, we demonstrated that mTag protein is degraded rapidly in cells. In addition, our work revealed that mTag did not physically interact with certain anti-oncoproteins. Finally, two potential HLA-A2.1-restricted functional epitopes within mTag sequence were identified. Our results show that mTag lacks the oncogenicity of full-length Tag and harbors potential HLA-A2.1-restricted immunogenic epitopes, hence suggesting the safety of vac-mTag for use in cancer immunotherapy.

Keywords: cancer immunotherapy; modified SV-40 T antigen; recombinant vaccinia

References

  1. Cancer Res. 1993 Mar 1;53(5):985-91 - PubMed
  2. J Exp Med. 1992 Dec 1;176(6):1693-702 - PubMed
  3. Biochem Biophys Res Commun. 1999 Apr 2;257(1):168-76 - PubMed
  4. Oncogene. 2002 Feb 14;21(8):1141-9 - PubMed
  5. Lancet. 2003 May 3;361(9368):1565; author reply 1565-6 - PubMed
  6. Curr Oncol Rep. 2003 Sep;5(5):372-9 - PubMed
  7. J Natl Cancer Inst. 1999 Jan 20;91(2):119-34 - PubMed
  8. Mol Ther. 2005 Feb;11(2):180-95 - PubMed
  9. Virology. 1988 Feb;162(2):427-36 - PubMed
  10. Cancer Immunol Immunother. 2007 Aug;56(8):1193-205 - PubMed
  11. Vaccine. 2007 Jan 2;25(1):34-42 - PubMed
  12. J Virol. 1983 Jul;47(1):115-24 - PubMed
  13. J Virol. 1995 Nov;69(11):6665-77 - PubMed
  14. Mol Cell Biol. 1987 Dec;7(12):4453-63 - PubMed
  15. Cancer Res. 2001 Feb 1;61(3):873-9 - PubMed
  16. Oncogene. 1997 Oct 16;15(16):1877-88 - PubMed
  17. J Virol. 2003 May;77(9):5039-45 - PubMed
  18. Semin Cancer Biol. 2001 Feb;11(1):49-61 - PubMed
  19. Lab Invest. 1988 May;58(5):518-23 - PubMed
  20. Rev Med Virol. 2000 Jan-Feb;10(1):31-43 - PubMed
  21. Oncogene. 2005 Nov 21;24(52):7729-45 - PubMed
  22. J Natl Cancer Inst. 1999 Jan 20;91(2):169-75 - PubMed

Publication Types

Grant support